A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

Trial Profile

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed; Tremelimumab
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms POSEIDON
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Jun 2018 Planned End Date changed from 12 Jul 2021 to 24 Sep 2021.
    • 20 Jun 2018 Planned primary completion date changed from 31 Jul 2019 to 30 Sep 2019.
    • 22 May 2018 Planned number of patients changed from 801 to 1000.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top